Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum

M Kunin; F Salamon; M Weinberger; I Genkin; A Sagie; R Tur-Kaspa

doi:10.1007/s10096-002-0763-8

Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum

Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):539-41. doi: 10.1007/s10096-002-0763-8. Epub 2002 Jul 10.

Authors

M Kunin¹, F Salamon, M Weinberger, I Genkin, A Sagie, R Tur-Kaspa

Affiliation

¹ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 12172746
DOI: 10.1007/s10096-002-0763-8

Abstract

Described here is the case of a patient with infective endocarditis in a prosthetic valve due to a Mycobacterium fortuitum-group organism. The patient was treated medically and had a favorable clinical response. This is only the second report of survival after Mycobacterium fortuitum-group endocarditis, and the first of survival without surgical intervention. The duration of treatment is not well defined for this patient, but life-long suppressive therapy will likely be required.

Publication types

Review

MeSH terms

Aged
Amikacin / therapeutic use
Anti-Bacterial Agents / therapeutic use
Ciprofloxacin / therapeutic use
Endocarditis, Bacterial / drug therapy*
Endocarditis, Bacterial / microbiology*
Heart Valve Prosthesis / microbiology*
Humans
Male
Meropenem
Mycobacterium Infections / drug therapy*
Mycobacterium Infections / microbiology
Mycobacterium fortuitum / isolation & purification*
Prosthesis-Related Infections / drug therapy*
Prosthesis-Related Infections / microbiology*
Thienamycins / therapeutic use

Substances

Anti-Bacterial Agents
Thienamycins
Ciprofloxacin
Amikacin
Meropenem